Skip to main content
Premium Trial:

Request an Annual Quote

International Health to Offer Provista's Breast Cancer Test in UK, Ireland

NEW YORK (GenomeWeb News) – Provista Life Sciences said today that International Health Technology will offer its early-stage breast cancer detection test in the United Kingdom and in Ireland.
 
Under the license agreement, IHT will offer the blood-based Biomarker Translation Test in its BreastHealth UK clinic this summer. The company said it plans to expand the availability of the test to other European Union countries sometime later, but did not provide further details on its timeline.
 
The company’s BT Test identifies multiple cancer-related proteins in blood samples and combines that information with the patient’s medical profile.
 
Phoenix, Ariz.-based Provista also said the test showed an accuracy rate above 80 percent for all women.
 
Financial terms of the agreement were not released.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.